Narayana Gowda, MD
Internal Medicine · Athens, GANPI 1417341090
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,067 of the $3,409 with a category attached, or 60.6%. 24 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 57.7% of the total. 2025 is the largest year on record at $1,781, more than ten times the $34 reported in 2019.
Across 80 payments — averaging $42.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- AstraZeneca$276
- GSK$147
- Actelion Pharmaceuticals US, Inc.$120
- Sanofi$99
- Regeneron Healthcare Solutions, Inc.$85
- plus $714 from 18 others
Across 23 payments — averaging $295.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$7K
What the payments were for
- Travel & lodging$1,34339%
- Food & beverage$2,06761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 19 | $1,968 |
| AstraZeneca | 10 | $276 |
| GSK | 8 | $147 |
| Actelion Pharmaceuticals US, Inc. | 6 | $120 |
| Sanofi | 3 | $99 |
| Regeneron Healthcare Solutions, Inc. | 4 | $85 |
| Insmed, Inc. | 3 | $83 |
| Harmony Biosciences LLC | 3 | $73 |
| Merck | 3 | $68 |
| Boehringer Ingelheim | 2 | $64 |
| United Therapeutics Corporation | 1 | $60 |
| Grifols USA, LLC | 3 | $59 |
| Mylan Specialty L.p. | 3 | $49 |
| Abbott | 1 | $45 |
| Johnson & Johnson | 2 | $34 |
| Baxter Healthcare | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Haemonetics Corporation | 1 | $22 |
| Bayer | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Shionogi Inc | 1 | $20 |
| Amgen | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$1,493
- Inspire Upper Airway Stimulation System$140
- TEZSPIRE$127
How this compares
$3,409 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $91,338 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $15,106 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,244 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $7,763 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $5,763 |
| Atrovent HfaIpratropium Bromide | 13 | $5,743 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,626 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 204 | $5,473 |
| Wixela InhubFluticasone Propion/Salmeterol | 33 | $3,090 |
| Ventolin HfaAlbuterol Sulfate | 23 | $1,427 |
| Montelukast Sodium | 42 | $665 |
| Fluticasone Propionate | 71 | $569 |
| Levocetirizine Dihydrochloride | 34 | $252 |
| Azelastine Hcl | 12 | $184 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $147 | $114,207168 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $276 | $16,87035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Athens
- Asif QadriAthens$18K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.